HealthCare and Roche Diagnostics have entered into a Memorandum of Understanding (MOU) that will leverage the strengths and resources of both companies to bring innovative solutions and increase access to precision care to cancer patients in key markets in Southeast Asia, Korea, Australia and New Zealand..

HealthCare和Roche Diagnostics已签署谅解备忘录（MOU），该备忘录将利用两家公司的优势和资源，为东南亚、韩国、澳大利亚和新西兰的关键市场的癌症患者带来创新解决方案，并增加精准护理的机会。。

This collaboration aims to combine GE HealthCare’s leadership in enterprise care solutions in oncology with Roche Diagnostics’ strength in advanced pathology lab solutions including digital pathology to provide more accurate and comprehensive diagnostic solutions across the care continuum in oncology..

此次合作旨在将GE HealthCare在肿瘤学企业护理解决方案方面的领先地位与罗氏诊断公司在先进病理学实验室解决方案（包括数字病理学）方面的优势相结合，在肿瘤学护理连续体中提供更准确和全面的诊断解决方案。。

Cancer continues to exert a significant burden on economies in Asia Pacific. Lung and breast cancer are the top two cancers in Asia1 with high mortality rates – lung cancer accounts for 20.9% of cancer deaths in Asia while breast cancer accounts for 5.8%. However, early diagnosis can significantly improve the prognosis for patients, with a majority of patients with lung cancer and breast cancer surviving their disease for five years or more, if diagnosed in its earliest stages.2,3.

癌症继续给亚太地区的经济体带来沉重负担。肺癌和乳腺癌是亚洲死亡率最高的两种癌症，肺癌占亚洲癌症死亡人数的20.9%，乳腺癌占5.8%。然而，早期诊断可以显着改善患者的预后，如果在早期诊断，大多数肺癌和乳腺癌患者的疾病存活五年或更长时间。2,3。

The collaboration between GE HealthCare and Roche Diagnostics Asia Pacific will seek to enable more precise and timely detection of both diseases and will aim to reduce diagnosis and treatment delays that can impact survival rates. GE HealthCare’s extensive portfolio in Imaging and oncology care pathways complemented with Roche Diagnostics’ expertise in Digital Pathology will help improve accuracy, enhance multidisciplinary team collaboration, provide advanced image analysis through artificial intelligence (AI), and ensure remote access to pathologists for cancer diagnosis.

GE HealthCare和Roche Diagnostics Asia Pacific之间的合作将寻求更精确和及时地检测这两种疾病，并旨在减少可能影响生存率的诊断和治疗延迟。GE HealthCare在成像和肿瘤学护理途径方面的广泛投资组合，以及罗氏诊断公司在数字病理学方面的专业知识，将有助于提高准确性，增强多学科团队合作，通过人工智能（AI）提供高级图像分析，并确保远程访问病理学家进行癌症诊断。

This has the potential to lead to reduced costs to healthcare professionals and faster and more accurate diagnosis, which could lead to timely and more tailored treatments for patients..

这有可能降低医疗保健专业人员的成本，更快，更准确的诊断，从而为患者提供及时，更具针对性的治疗。。

Dr Anthony Lawrence, Chief Strategy and Marketing Officer for GE HealthCare in ASEAN, Korea, Australia, and New Zealand said: “This collaboration with Roche Diagnostics in Asia Pacific marks a significant step forward in our commitment to building a comprehensive ecosystem in oncology with complementing solutions from partners in adjacent fields who are also leaders in their disciplines.

GE HealthCare在东盟、韩国、澳大利亚和新西兰的首席战略和营销官安东尼·劳伦斯博士表示：“与罗氏诊断公司在亚太地区的合作标志着我们在致力于构建肿瘤学综合生态系统方面迈出了重要一步，并补充了相邻领域合作伙伴的解决方案，这些合作伙伴也是其学科的领导者。

Together, we aim to provide innovative end-to-end solutions across the entire care pathway – from screening, diagnosis, treatment and monitoring – and set new benchmarks in healthcare accessibility and quality, ultimately contributing to healthier communities across the region.”.

总之，我们的目标是在整个护理途径（从筛查、诊断、治疗和监测）中提供创新的端到端解决方案，并在医疗保健的可及性和质量方面设定新的基准，最终为整个地区的健康社区做出贡献。”。

Christopher Chiam, Asia Pacific Head of Digital Health Solutions, said: “At Roche Diagnostics, we are committed to introducing innovative solutions that address the challenges faced by patients today, so that they can live longer, better lives. Through this collaboration we will help improve early detection and personalized treatment and ultimately enhance patient access to latest healthcare solutions and improve outcomes.

数字健康解决方案亚太区负责人克里斯托弗·奇姆（Christopher Chiam）表示：“在罗氏诊断公司，我们致力于推出创新解决方案，以应对当今患者面临的挑战，使他们能够活得更长、更好。通过这项合作，我们将帮助改善早期发现和个性化治疗，并最终增强患者获得最新医疗保健解决方案的机会，改善预后。

We are excited to collaborate with GE HealthCare in our efforts to expand patient access to diagnostic and imaging technologies in Asia.”.

我们很高兴与GE HealthCare合作，努力扩大亚洲患者对诊断和成像技术的访问。”。

About GE HealthCare Technologies Inc.

关于GE HealthCare Technologies Inc。

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

GE HealthCare是全球领先的医疗技术、药物诊断和数字解决方案创新者，致力于提供集成的解决方案、服务和数据分析，使医院更高效、临床医生更有效、治疗更精确，患者更健康、更快乐。

Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound and Image Guided Therapies, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring.

GE HealthCare为患者和提供者服务了125多年，正在推进个性化、互联化和富有同情心的护理，同时简化患者跨越护理路径的旅程。我们的成像、超声波和图像引导疗法、患者护理解决方案和药物诊断业务共同帮助改善患者护理，从诊断到治疗再到监测。

We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits..

我们是一家价值196亿美元的企业，拥有约51000名员工，致力于创造一个医疗保健无限的世界。。